Improvement Effects of Myelophil on Symptoms of Chronic Fatigue Syndrome in a Reserpine-Induced Mouse Model.
Song, Ji-Hye, Won, Seul-Ki, Eom, Geun-Hyang et al. · International journal of molecular sciences · 2021 · DOI
Quick Summary
Researchers tested a herbal mixture called myelophil (made from two traditional medicinal plants) in mice engineered to show ME/CFS-like symptoms including fatigue, pain, and depression. The treatment improved all three symptoms and appeared to work by increasing important brain chemicals like dopamine and serotonin, reducing inflammation, and protecting against cell damage. While these results are encouraging, this study was only in mice, so it's too early to know if the same benefits would occur in people with ME/CFS.
Why It Matters
ME/CFS lacks approved treatments and understanding of underlying biology. This study provides preclinical evidence for a multi-target mechanism involving neurotransmitter dysregulation and neuroinflammation, potentially informing future therapeutic development and clinical trial design for ME/CFS.
Observed Findings
MYP treatment improved depression-like behaviors, mechanical pain sensitivity, thermal pain sensitivity, and fatigue-related activity in reserpine-exposed mice.
MYP increased dopamine and serotonin levels in the striatum and elevated tyrosine hydroxylase expression.
MYP reduced Iba1 (a microglial activation marker) in the hippocampus.
MYP regulated 5-HT1A/B serotonin receptors and TGF-β expression in multiple brain regions.
MYP altered inflammatory and anti-oxidant gene expression in spleen and liver tissues.
Inferred Conclusions
MYP ameliorates depression, pain, and fatigue symptoms via dopaminergic and serotonergic pathway modulation.
MYP's mechanisms include reduction of neuroinflammation (microglial activation) and regulation of growth factor signaling.
Systemic anti-inflammatory and anti-oxidant effects in peripheral organs may contribute to symptom improvement.
The multi-target effects suggest MYP may address multiple biological dysfunctions implicated in ME/CFS.
Remaining Questions
Would myelophil show efficacy in human ME/CFS patients, and at what doses?
What This Study Does Not Prove
This study does not prove that myelophil is effective in humans with ME/CFS—it only demonstrates effects in a mouse model. The reserpine model captures some ME/CFS symptoms but not the full complexity of the disease. Correlation between observed molecular changes and symptom improvement does not establish causation.